BeBetter Med Appoints Dr. Weijia Sun as Chief Medical Officer

Share Article

BeBetter Med announced today the appointment of Dr. Weijia Sun as Chief Medical Officer. In this role, Dr. Weijia Sun will lead BeBetter’s new drug clinical trials and registration. He will report to Dr. Changgeng Qian, CEO of BeBetter Med

Dr. Sun brings over 30-year experience in general surgery, clinical medicine, teaching and scientific research in China. He is a Chief Physician and Professor at Central South University. Prior to join BeBetter Med, he served as Executive Vice President of Xiangya Medical College, Director of the Institute of Pancreatic Diseases at Central South University, Vice President of Xiangya Hospital, and Director of the Medical Management Office of Central South University. Currently, he is Executive Director of China Health Education Association, Vice Chairman of Health Education Expert Committee for China Hospitals, and Associate Editor of Chinese Journal of General Surgery. He was a leader for the Key National Project on General Surgery at Xiangya Hospital. Dr. Sun obtained a MD from the Central South University and worked as a visiting scholar at the Medical School of the University of Miami for two years.

“We are delighted to welcome Dr. Sun to BeBetter Med. He is well known and respected in clinical medicine in China. We will benefit tremendously from his leadership in Chinese medical societies and depth of experience in medical management and drug clinical trials,” said Dr. Qian. “I look forward to working together as we advance BeBetter’s multiple drug candidates from discovery to development.”

About BeBetter Med
Guangzhou BeBetter Medicine Technology Co., LTD is a drug discovery and development company founded in 2012 by overseas returnees and aims to create advanced novel medicines to treat cancer and other challenging diseases. The company has strong expertise and outstanding facilities to conduct comprehensive pharmaceutical research from chemical synthesis to clinical evaluation. Several innovative drug candidates with own IP rights are entering IND filings and clinical trials. The company's leading anti-cancer drug candidate, BEBT-908, is expected to enter phase II clinical trial in China during the 2nd half of the year. To learn more, please visit http://www.bebettermed.com.

Contact:
Connie Fu Ph.D., MBA.
CFO & CBO
BeBetter Med Co, LTD.
25 Yayingshi Road, Science City
Guangzhou, China 510660
Phone: 86-20-3665-7220
Email: cfu@bebettermed.com

Share article on social media or email:

View article via:

Pdf Print